A Network Meta-Analysis Comparing Osteoporotic Fracture among Different Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There are limited studies comparing the risk of osteoporosis and fractures between different direct oral anticoagulants (DOACs) and vitamin K antagonists (VKA) in non-valvular atrial fibrillation (AF). Using a network meta-analysis (NMA), we compared osteoporotic fractures among 5 different treatment arms, viz. dabigatran, rivaroxaban, apixaban, edoxaban, and VKA. Methods: Ten studies, including 5 randomized control trials and 5 population-based studies, with a total of 321,844 patients (148,751 and 173,093 in the VKA and DOAC group, respectively) with a median follow-up of 2 years, were included. A Bayesian random-effects NMA model comparing fractures among the treatment arms was performed using MetInsight V3. Sensitivity analysis excluded studies with the highest residual deviances from the NMA model. Results: The mean age of the patients was 70 years. The meta-analysis favored DOACs over VKA with significantly lower osteoporotic fracture (odds ratio [OR], 0.77; 95% credible interval [CrI], 0.70-0.86). The NMA demonstrated that fractures were significantly lower with apixaban compared with dabigatran (OR, 0.64; 95% CrI, 0.44-0.95); however, fractures were statistically similar between apixaban and rivaroxaban (OR, 0.84; 95% CrI, 0.58-1.24) and dabigatran and rivaroxaban (OR, 1.32; 95% CrI, 0.90-1.87). Based on the Bayesian model of NMA, the probability of osteoporotic fracture was highest with VKA and lowest with apixaban, followed by rivaroxaban, edoxaban, and dabigatran. Conclusions: The decision to prescribe anticoagulants in elderly patients with AF should be made not only based on thrombotic and bleeding risks but also on the risk of osteoporotic fracture; these factors should be considered and incorporated in contemporary cardiology practice.
Abstract
Background: There are limited studies comparing the risk of osteoporosis and fractures between different direct oral anticoagulants (DOACs) and vitamin K antagonists (VKA) in non-valvular atrial fibrillation (AF). Using a network meta-analysis (NMA), we compared osteoporotic fractures among 5 different treatment arms, viz. dabigatran, rivaroxaban, apixaban, edoxaban, and VKA. Methods: Ten studies, including 5 randomized control trials and 5 population-based studies, with a total of 321,844 patients (148,751 and 173,093 in the VKA and DOAC group, respectively) with a median follow-up of 2 years, were included. A Bayesian random-effects NMA model comparing fractures among the treatment arms was performed using MetInsight V3. Sensitivity analysis excluded studies with the highest residual deviances from the NMA model. Results: The mean age of the patients was 70 years. The meta-analysis favored DOACs over VKA with significantly lower osteoporotic fracture (odds ratio [OR], 0.77; 95% credible interval [CrI], 0.70-0.86). The NMA demonstrated that fractures were significantly lower with apixaban compared with dabigatran (OR, 0.64; 95% CrI, 0.44-0.95); however, fractures were statistically similar between apixaban and rivaroxaban (OR, 0.84; 95% CrI, 0.58-1.24) and dabigatran and rivaroxaban (OR, 1.32; 95% CrI, 0.90-1.87). Based on the Bayesian model of NMA, the probability of osteoporotic fracture was highest with VKA and lowest with apixaban, followed by rivaroxaban, edoxaban, and dabigatran. Conclusions: The decision to prescribe anticoagulants in elderly patients with AF should be made not only based on thrombotic and bleeding risks but also on the risk of osteoporotic fracture; these factors should be considered and incorporated in contemporary cardiology practice.
참고문헌 (41)
- Julia Sikorska, "Direct Oral Anticoagulants: A Quick Guide", European Cardiology Review, 12(1), pp.40~45 (2017), Radcliffe Group Ltd[DOI]
- G. D. Barnes, "Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply", Journal of Thrombosis and Haemostasis, 13(11), pp.2132~2133 (2015), Wiley[DOI]
- Salvatore Santo Signorelli, "Anticoagulants and Osteoporosis", International Journal of Molecular Sciences, 20(21), pp.5275~ (2019), MDPI AG[DOI]
- Flavia Mayer, "Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy", Journal of the American Heart Association, 7(6), pp.e008034~ (2018), Ovid Technologies (Wolters Kluwer Health)[DOI]
- N.B. Kavukcuoglu, "Effect of osteocalcin deficiency on the nanomechanics and chemistry of mouse bones", Journal of the Mechanical Behavior of Biomedical Materials, 2(4), pp.348~354 (2009), Elsevier BV[DOI]
- Purificación Rey-Sánchez, "Ultrasound bone mass in schizophrenic patients on antipsychotic therapy", Human Psychopharmacology: Clinical and Experimental, 24(1), pp.49~54 (2009), Wiley[DOI]
- Toshihiro Sugiyama, "Warfarin-induced impairment of cortical bone material quality and compensatory adaptation of cortical bone structure to mechanical stimuli", Journal of Endocrinology, 194(1), pp.213~222 (2007), Bioscientifica[DOI]
- Toshihiro Sugiyama, "Carboxylation of osteocalcin may be related to bone quality: a possible mechanism of bone fracture prevention by vitamin K", Journal of Bone and Mineral Metabolism, 19(3), pp.146~149 (2001), Springer Science and Business Media LLC[DOI]
- P. J. Caraballo, "Changes in Bone Density after Exposure to Oral Anticoagulants: A Meta-analysis", Osteoporosis International, 9(5), pp.441~448 (1999), Springer Science and Business Media LLC[DOI]
- N. Veronese, "Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis", Journal of Thrombosis and Haemostasis, 13(9), pp.1665~1675 (2015), Wiley[DOI]
- Gordon H Guyatt, "Going from evidence to recommendations", BMJ, 336(7652), pp.1049~1051 (2008), BMJ[DOI]
- Wendy Fiordellisi, "A Systematic Review and Meta-analysis of the Association Between Vitamin K Antagonist Use and Fracture", Journal of General Internal Medicine, 34(2), pp.304~311 (2019), Springer Science and Business Media LLC[DOI]
- Stuart J. Connolly, "Dabigatran versus Warfarin in Patients with Atrial Fibrillation", New England Journal of Medicine, 361(12), pp.1139~1151 (2009), Massachusetts Medical Society[DOI]
- Manesh R. Patel, "Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation", New England Journal of Medicine, 365(10), pp.883~891 (2011), Massachusetts Medical Society[DOI]
- Masatsugu Hori, "Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation", Circulation Journal, 76(9), pp.2104~2111 (2012), Japanese Circulation Society[DOI]
- Christopher B. Granger, "Apixaban versus Warfarin in Patients with Atrial Fibrillation", New England Journal of Medicine, 365(11), pp.981~992 (2011), Massachusetts Medical Society[DOI]
- Robert P. Giugliano, "Edoxaban versus Warfarin in Patients with Atrial Fibrillation", New England Journal of Medicine, 369(22), pp.2093~2104 (2013), Massachusetts Medical Society[DOI]
- Lindsay G.S. Bengtson, "Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation", Journal of Cardiology, 69(6), pp.868~876 (2017), Elsevier BV[DOI]
- Wallis C. Y. Lau, "Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation", JAMA, 317(11), pp.1151~1158 (2017), American Medical Association (AMA)[DOI]
- Faye L. Norby, "Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation", BMC Cardiovascular Disorders, 17(1), pp.238~ (2017), Springer Science and Business Media LLC[DOI]
- Pamela L. Lutsey, "Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation", JAMA Internal Medicine, 180(2), pp.245~253 (2020), American Medical Association (AMA)[DOI]
- Satoshi Yokoyama, "Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach", International Journal of Medical Sciences, 17(4), pp.471~479 (2020), Ivyspring International Publisher[DOI]
- Wallis C.Y. Lau, "Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation", Annals of Internal Medicine, 173(1), pp.1~9 (2020), American College of Physicians[DOI]
- A. Liberati, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration", BMJ, 339, pp.b2700~b2700 (2009), BMJ[DOI]
- Jonathan A C Sterne, "RoB 2: a revised tool for assessing risk of bias in randomised trials", BMJ, 366, pp.l4898~ (2019), BMJ[DOI]
- "The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses" (2009)[URL]
- Sommer H, "Use R! an introduction to meta-analysis with R. Filtering the information overload for better decisions", The 23rd Cochrane Colloquium (2015), John Wiley & Sons
- Rhiannon K. Owen, "MetaInsight: An interactive web‐based tool for analyzing, interrogating, and visualizing network meta‐analyses using R‐shiny and netmeta", Research Synthesis Methods, 10(4), pp.569~581 (2019), Wiley[DOI]
- Don van Ravenzwaaij, "A simple introduction to Markov Chain Monte–Carlo sampling", Psychonomic Bulletin & Review, 25(1), pp.143~154 (2018), Springer Science and Business Media LLC[DOI]
- Stephen P. Brooks, "General Methods for Monitoring Convergence of Iterative Simulations", Journal of Computational and Graphical Statistics, 7(4), pp.434~455 (1998), Informa UK Limited[DOI]
- Dapeng Hu, "How to Conduct a Bayesian Network Meta-Analysis", Frontiers in Veterinary Science, 7, pp.271~ (2020), Frontiers Media SA[DOI]
- Shannon Cope, "Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making", BMC Medical Research Methodology, 13(1), pp.147~ (2013), Springer Science and Business Media LLC[DOI]
- Sofia Dias, "Evidence Synthesis for Decision Making 4", Medical Decision Making, 33(5), pp.641~656 (2013), SAGE Publications[DOI]
- David C. Wheeler, "Assessing local model adequacy in Bayesian hierarchical models using the partitioned deviance information criterion", Computational Statistics & Data Analysis, 54(6), pp.1657~1671 (2010), Elsevier BV[DOI]
- Binding C, "Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants", J Am Coll Cardiol, 74, pp.2150~2158 (2019)[DOI]
- Huei-Kai Huang, "Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study", European Heart Journal, 41(10), pp.1100~1108 (2020), Oxford University Press (OUP)[DOI]
- Maria Fusaro, "Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal Function", PLOS ONE, 10(8), pp.e0133847~ (2015), Public Library of Science (PLoS)[DOI]
- Zhi-Chun Gu, "Non-vitamin K antagonist oral anticoagulants vs. warfarin at risk of fractures: A systematic review and meta-analysis of randomized controlled trials", Frontiers in Pharmacology, 9, pp.348~ (2018), Frontiers Media SA[DOI]
- Thomas C. Dahlman, "Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin", American Journal of Obstetrics and Gynecology, 168(4), pp.1265~1270 (1993), Elsevier BV[DOI]
- María-Isabel Jiménez-Serranía, "New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof", Seminars in Thrombosis and Hemostasis, 45(02), pp.196~204 (2019), Georg Thieme Verlag KG[DOI]
- Huei‐Kai Huang, "Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin", Journal of the American Heart Association, 9(2), pp.e013845~ (2020), Ovid Technologies (Wolters Kluwer Health)[DOI]